Menu Search
Equities

Serina Therapeutics Inc

0X4:STU

Serina Therapeutics Inc

Actions
  • Price (EUR)13.72
  • Today's Change2.02 / 17.26%
  • Shares traded0.00
  • 1 Year change+3.46%
  • Beta--
Data delayed at least 15 minutes, as of Mar 14 2024.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Serina Therapeutics, Inc., formerly AgeX Therapeutics, Inc., is a clinical-stage biotechnology company. The Company is engaged in developing a pipeline of wholly owned drug product candidates to treat neurological diseases and pain. Its POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. Its POZ Platform partners are at the forefront in advancing LNP delivery technology to develop RNA therapeutics. The Company is focused on the advancement of its lead drug candidate, SER-252 (POZ-apomorphine), for the treatment of advanced Parkinson’s Disease through pre-clinical studies. The Company intends to advance SER 252 into Phase I clinical trials.

  • Revenue in USD (TTM)137.00k
  • Net income in USD-20.96m
  • Incorporated2017
  • Employees4.00
  • Location
    Serina Therapeutics Inc1101 MARINA VILLAGE PARKWAY, SUITE 201ALAMEDA 94501United StatesUSA
  • Phone+1 (510) 671-8370
  • Websitehttps://www.agexinc.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		SER:ASQ since
announced		Transaction
value
Serina Therapeutics IncDeal completed30 Aug 202330 Aug 2023Deal completed-64.27%90.00m
Data delayed at least 15 minutes, as of Jun 03 2024 15:09 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.